The agreement requires Lundbeck to register and commercialise key products which are currently available in the US and/or Europe on behalf of Cephalon including Fentora (fentanyl buccal tablet) [C-II], Provigil, Treanda, Trisenox (arsenic trioxide) injections, Myocet (liposomal- doxorubicin) and Nuvigil.
Treanda, Nuvigil (armodafinil) Tablets [C-IV] and Provigil (modafinil) Tablets [C-IV] represent attractive product opportunities of adding significant sales in Canada and Latin America for the company.
Lundbeck will pay double-digit royalties on sales which will be the main revenue stream for Cephalon from these products in these territories.
Lundbeck president and CEO Ulf Wiinberg said the Cephalon brands will significantly strengthen the company’s position in these markets while leveraging on existing sales and marketing capabilities adding significant sales in Canada and Latin America from 2012.